| Summary: | Background
To determine the efficacy and safety of Vernonia
cinerea (L.) Less. for smoking
cessation using a systematic review and meta-analysis approach.
Methods
Data sources: Nine databases were searched through April 2017.
Study selection: Randomized controlled trials that reported the clinical effect of V. cinerea . for smoking cessation were included.
Data extraction: Important data and outcomes were extracted by two independent
researchers. Study quality was assessed using the Cochrane risk of bias tool and
JADAD score.
Results
Data synthesis: Five trials with 347 active smokers were included. Two trials were
rated as low risk of bias in all domains while others were rated as some concerns. V. cinerea treatment group was associated with significant
cessation rate higher than that in the control group with no evidence of
heterogeneity for both continuous abstinence rate (CAR) (week 8 risk ratio (RR): 1.69, 95% CI [1.00,
2.86]; week 12 RR: 2.18, 95% CI [1.17, 4.04]) and 7-day point prevalence abstinence rate (PAR) (week 8 RR: 1.51, 95%
CI [1.01, 2.27]; week 12 RR: 1.93, 95% CI [1.24, 2.99]) at week 8 and 12,
respectively. There was no significant
difference of all adverse events between treatment and control groups.
Conclusions
This comprehensive systematic review and meta-analysis suggests that V. cinerea might be considered as a
potential alternative for smoking cessation treatment. Further well-design RCTs
of standardized V.
cinerea compared
with standard treatment should be conducted to strengthen this evidence.
|
|---|
